Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology ConferenceBusiness Wire • 02/01/23
Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)Zacks Investment Research • 12/30/22
Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 12/14/22
Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidateMarket Watch • 12/12/22
What Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing'Zacks Investment Research • 12/07/22
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Business Wire • 12/02/22
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology SummitBusiness Wire • 11/30/22
Wall Street Analysts Think Adicet Bio, Inc. (ACET) Could Surge 72%: Read This Before Placing a BetZacks Investment Research • 11/29/22
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory OfficerBusiness Wire • 11/29/22
Wall Street Analysts See a 39% Upside in Adicet Bio, Inc. (ACET): Can the Stock Really Move This High?Zacks Investment Research • 11/11/22
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/09/22
Adicet Reports Third Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 11/08/22
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingBusiness Wire • 11/07/22
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Business Wire • 11/03/22
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingBusiness Wire • 10/05/22
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/22
Adicet Reports Second Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 08/10/22
Adicet Bio, Inc. (ACET) Is a Great Choice for "Trend" Investors, Here's WhyZacks Investment Research • 07/18/22
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual MeetingBusiness Wire • 06/06/22